PHARMACIA & UPJOHN TO FILE NDA FOR UPJOHN's CAMPTOSAR (IRINOTECAN) FOR CANCER IN OCTOBER; NDA FILINGS FOR UPJOHN's DRUGS REMISAR AND PRAMIPEXOLE TO FOLLOW
Executive Summary
Pharmacia & Upjohn plans to file an NDA for the anti-cancer agent Camptosar (irinotecan) in October, according to an Aug. 21 presentation to securities analysts in New York City on the merger of Pharmacia and Upjohn. The merger was announced Aug. 20.